Выявление мутаций в генах K-ras, B-raf и APC при некоторых онкологических заболеваниях

Список литературы

1. Matherials of «1st International Symposium on Signal Transduction Modulators in
2. Cancer Therapy», September 23−25,2002, Amsterdam, The Netherlands.
3. Mandel P., Metais P. Les acides nucleiques du plasma sanguine chez l’Homme. CR
4. Acad. Sci. Paris 1948- 142: 241−3.
5. Stroun M., Anker P., Maurice P. et al. Neoplastic characteristics of the DNA found inthe plasma of cancer patients. Oncol. 1989- 46: 318−22.
6. Shapiro В., Chakrabarty M., Cohn E. M. et al. Determination of circulating DNAlevels in patients with benign or malignant gastrointestinal disease. Cancer 1983- 51:2116−20.
7. Anker P., Lefort F., Vasioukhin V. et al. K-ras gene mutationsin the plasma ofcolorectal cancer patients. Gastroenterology 1997- 112: 1114−20.
8. Hahn W. C., Weinberg R. A. Modelling the molecular circuitry of cancer. Nature
9. Rev. Cancer 2002- 2: 331−41.
10. Hanahan D" Weinberg R. A. The hallmarks of cancer. Cell 2000- 100: 57−70.
11. Nebert D. W. Transcription factors and cancer: an overview. Toxicology 2002- 181 182: 131−41.
12. Bishop J. M. Molecular themes in oncogenesis. Cell 1991- 64: 235−48.
13. Levine A. J. The tumor suppressor genes. Annu. Rev. Biochem. 1993- 62: 623−51.
14. Rabbits Т. H.. Nature 1994- 72: 143−49.
15. Weinberg R. A. The molecular basis of oncogenes and tumor suppressor genes.
16. Ann. N. Y. Acad. Sci. 1995- 758: 331−8.
17. Hunter T. Oncoprotein networks. Cell 1997- 88: 333−46.
18. Hooper M. L. Pyk2 and Src-family protein-tyrosine kinases compensate for the lossof FAK in fibronectin-stimulated signaling events but Pyk2 does not fully function to enhance FAK- cell migration. EMBO J. 1998- 17: 6783−9.
19. Harvey J. J. An unidentified virus which causes the rapid production of tumors inmice. Nature 1964- 204: 1104−5.
20. Kirsten W. H. and Mayer L. A. Morphologic responses to a murine erythroblastosisvirus. J. Natl. Cancer Inst. 1967- 39: 311−35.
21. Shih T. Y., Weeks M. O., Young H. A. et al. Identification of sarcoma virus-codedphosphoprotein in nonproducer cells transformed by Kirsten or Harvey murine sarcoma virus. Virology 1979- 96: 64−79.
22. Lowy D. R. and Willumsen В. M. Function and regulation of ras. Ann Rev Biochem1993- 62: 851−91.
23. Downward J. Ras signalling and apoptosis. Curr Opin Genet Dev 1998- 8: 49−54.
24. Khosravi-Far R., Campbell S., Rossman K. L. et al. Increasing complexity of Rassignal transduction: involvement of Rho family proteins. Adv Cancer Res 1998- 72: 57−107.
25. Bourne H. R., D. A. Sanders & F. McCormick: The GTPase superfamily: aconserved switch for diverse cell functions. Nature 1990- 348:125−32.
26. Bos J. L.: Ras-like GTPases. Biochim Biophys Acta 1997- 1333: M19−31.
27. Kimmelman A., T. Tolkacheva, M. V. Lorenzi, M. Osada & A. M.-L. Chan:1.entification and characterization of R-rayJ: a novel member of the RAS gene family with a non-ubiquitous pattern of tissue distribution. Oncogene 1997- 15: 2675−85.
28. Matsumoto К., T. Asano & T. Endo: Novel small GTPase M-Ras participates inreorganization of actin cytoskeleton. Oncogene 1997- 15: 2409−17.
29. Kitayama H., Y. Sugimoto, T. Matsuzaki, Y. Ikawa & M. Noda: A ras-related genewith transformation suppressor activity. Cell 1989- 56: 77−84.
30. Barbacid M.: ras genes. Ann Rev Biochem 1987- 56: 779−827.
31. Paciucci R. & A. Pellicer: Dissection of the mouse N-ras gene upstream regulatorysequences, overlapping with an adjacent gene. Mol Cell Biol 1991- 11: 1334−43.
32. Jeffers M. & A. Pellicer: Identification of multiple promoters within the N-ras protooncogene. Biochem Biophys Acta 1994- 1219: 623−35.
33. Cohen J. В., S. D. Broz & A. D. Levinson: Expression of the H-ras proto-oncogeneis controlled by alternative splicing. Cell 1989- 58: 461−72.
34. Leon J., I. Guerrero & A. Pellicer: Different expression of the ras gene family inmice. Mol Cell Biol 1987- 7: 1535−40.
35. Furth M. E., Т. H. Aldrich & C. Cordon-Cardo: Expression of ras proto-oncogeneproteins in normal human tissues. Oncogene 1987- 1: 47−58.
36. Pells S., M. Divjak, P. Romanowski, K. Impey, N. J. Hawkins, A. R. Clarke, M. L.
37. Hooper & D. J. Williamson: Developmentally-regulated expression of murine K-ras isoforms. Oncogene 1997- 15: 1781−86.
38. Scheele J. S., J. M. Rhee & G. R. Boss: Determination of absolute amounts of GDPand GTP bound to Ras in mammalian cells: comparison of parental and Ras-overproducing NIH 3T3 fibroblasts. Proc Natl Acad Sci USA 1995- 92: 10 971 100.
39. Quincoces A. F. & J. Leon: Serum growth factors up-regulate H-ras, K-ras, and Nras proto-oncogenes in fibroblasts. Cell Growth Differ 1995- 6: 271−79.
40. Quincoces A. F., I. Polanco, T. Thomson & J. Leon: Positive autoregulation of rasgenes expression in fibroblasts. FEBS Lett 1997- 416: 317−23.
41. Ulsh L. & T. Y. Shih: Metabolic turnover of human c-rasH p21 protein of EJ bladdercarcinoma and its normal cellular and viral homologs. Mol Cell Biol 1984- 4: 1647−52.
42. Casey, P. J., P. A. Solski, C. J. Der, and J. E. Buss. p21ras is modified by a farnesylisoprenoid. Proc. Natl. Acad. Sci. USA 1989- 86: 8323−7.
43. Gutierrez L" Magee A. I., Marshall C. J., Hancock J. F. Posttranslational processingof p21ras is two-step and involves carboxyl-methylation and carboxy-terminal proteolysis. EMBOJ1989- 8: 1093−8.
44. Willumsen В. M., Norris K., Papageorge A. G. et al. Harvey murine sarcoma virusp21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus. EMBO J 1984- 3: 2581−5.
45. Lacal P. M., Pennington C. Y., Lacal J. C. Transforming activity of ras proteinstranslocated to the plasma membrane by a myristoylation sequence from the src gene product. Oncogene 1988- 2: 533−7.
46. Roy, S., R. Luetterforst, A. Harding, A. Apolloni, M. Etheridge, E. Stang, B. Rolls,
47. J. F. Hancock, and R. G. Parton. 1999. Dominant-negative caveolin inhibits H-Ras function by disrupting cholesterol-rich plasma membrane domains. Nat. Cell Biol. 1:98−105.
48. Buss J. E., P. A. Solski, J. P. Schaeffer, M. J. MacDonald & C. J. Der: Activation ofthe cellular proto-oncogene product p21Ras by addition of a myristylation signal. Science 243, 1600−1603 (1989)
49. Bollag G. & F. McCormick: Regulators and effectors of ras proteins. Ann Rev Cell1. Biol 7,601−632(1991)
50. Boguski M. S. & F. McCormick: Proteins regulating Ras and its relatives. Nature366, 643−654 (1993)
51. Wittinghofer A. & E. Pai: The structure of Ras protein: a model for a universalmolecular switch. Trends Biochem Sci 16, 382−387 (1991)
52. Ma J. & M. Karplus: Molecular switch in signal transduction: reaction paths of theconformational changes in ras p21 .Proc Natl Acad Sci USA 94, 11 905−11 910 (1997)
53. Bos J. L.: ras oncogenes in human cancer: a review. Cancer Res 49,4682−46 891 989)
54. Rodenhuis S.: ras and human tumors. Semin Cancer Biol 3, 241−247 (1992)
55. Bos J. L., Fearon E. R., Hamilton S. R. et al. Prevalence of ras gene mutations inhuman colorectal cancers. Nature 1987- 327: 293−297.
56. Forrester K., Almoguera C., Han K. et al. Detection of high incidence of K-rasoncogenes during human colon tumorigenesis. Nature 1987- 327: 298−303.
57. Rashid A. Cellular and molecular biology of biliary tract cancers. Surg. Oncol. Clin.
58. N. Am. 2002- 11(4): 995−1009.
59. Tannapfel A, Benicke M, Katalinic A. et al. Frequency of pl6(INK4A) alterationsand K-ras mutations in intrahepatic cholangiocarcinoma of the liver. Gut 2000- 47: 721−727.
60. Moore P. S., Beghelli S., Zamboni G., Scarpa A. Genetic abnormalities in pancreaticcancer. Mol. Cancer 2003- 2(1): 7−13.
61. Cowgill SM, Muscarella P. The genetic of pancreatic cancer. Am. J. Surg.2003- 186(3): 279−286.
62. Zhang LF, Gao WM, Gealy R, Weissfeld J, Elder E, Whiteside TL, Keohavong P.
63. Comparison of K-ras gene mutations in tumour and sputum DNA of patients with lung cancer. Biomarkers 2003- 8(2): 156−161.
64. Kovalchuk O, Chyczewska E, Niklinska W, Niklinski J, Naumnik W, Chyczewski
65. K-ras codon 12 mutations with enriched PCR method in operable non-small cell lung cancer. Folia Histochem. Cytobiol. 2001- 39 suppl 2: 68−69.
66. Kinzler K. W. & B. Vogelstein: Lessons from hereditary colorectal cancer. Cell 87,159.170(1996)
67. Brandt-Rauf P. W., R. P. Carty, J. Chen, M. Avitable, J. Lubowsky & M. R. Pincus:
68. Structure of the carboxyl terminus of the RAS gene-encoded P21 proteins. Proc. Natl. Acad. Sci. USA 85, 5869−5873 (1988)
69. Mellersh H., A. J. Strain & D. J. Hill: Expression of the proto-oncogenes c-H-ras and
70. N-ras in early second trimester human fetal tissues. Biochem Biophys Res Commun 141,510−6(1986)
71. Tanaka Т., N. Ida, H. Shimoda, C. Waki, D. J. Slamon & M. J. Cline: Organ specificexpression of ras oncoproteins during growth and development of the rat. Mol Cell Biochem 70, 97−104 (1986)
72. Fiorucci G. & A. Hall: All three human ras genes are expressed in a wide range oftissues. Biochem. Biophys. Acta 950, 81−83 (1988)
73. Muller R., D. J. Slamon, E. D. Adamson, J. M. Tremblay, D. Muller, M. J. Cline &
74. M. Verma: Transcription of c-onc genes c-rasKi and c-fms during mouse development. Mol Cell Biol 3,1062−1069 (1983)
75. Delgado M. D., A. F. Quincoces, M. T. Gomez-Casares, C. A. Martinez, M. A.
76. Cuadrado, C. Richard & J. Leon: Differential expression of ras protooncogenesduring in vitro differentiation of human erythroleukemia cells. Cancer Res 52, 5979−84(1992)
77. Grand R. J. A. & D. Owen: The biochemistry of ras p21. BiochemJ 279, 609−6 311 991)
78. Mangues R., T. Corral, N. E. Kohl, W. F. Symmans, S. Lu, M. Malumbres, J. B.
79. Gibbs, A. Oliff & A. Pellicer: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ray in transgenic mice. Cancer Res 58,1253−1259 (1998)
80. Mizuno Т., К. Kaibuchi, Т. Yamamoto, M. Kawamura, T. Sakoda, H. Fujioka, Y.
81. Matsuura & Y. Takai: A stimulatory GDP/GTP exchange protein for smg p21 is active on the post-translationally processed form of c-Ki-ras p21 and rhoA p21. Proc. Natl. Acad. Sci. USA 88, 6442−6446 (1991)
82. Jones M. K. & J. H. Jackson: Ras-GRF activates Ha-Ras, but not N-Ras or K-Ras4B, protein In vivo. J Biol Chem 273,1782−1787 (1998)
83. Francis-Lang H., M. Zannini, M. De Felice, M. T. Berlingieri, A. Fusco & R. Di1. uro: Multiple mechanisms of interference between transformation and differentiation in thyroid cells. Mol Cell Biol 12, 5793−5800 (1992)
84. Yan Z., M. Chen, M. Perucho & E. Friedman: Oncogenic Ki-ras but not oncogenic
85. Ha-ray blocks integrin? 1-chain maturation in colon epithelial cells. J Biol Chem 272,30 928−30936(1997)
86. Yan Z" X. Deng, M. Chen, Y. Xu, M. Ahram, B. F. Sloane & E. Friedman:
87. Oncogenic c-Ki-ras but not oncogenic c-Ha-ray up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. J Biol Chem 272,27 902−27907(1997)
88. Hamilton M. & A. Wolfman: Ha-ras and N-ras regulate МАРК activity by distinctmechanisms In vivo. Oncogene 16, 1417−1428 (1998)
89. Pawson Т.: Protein modules and signalling networks. Nature 373, 573−580 (1995)
90. Bonfini L., E. Migliaccio, G. Pellici, L. Lanfrancone & P. G. Pelicci: Not all She’sroads lead to Ras. Trends Biochem Sci 21, 257−261 (1996)
91. Lopez-Ilasaca M., P. Crespo, P. G. Pellici, J. S. Gutkind & R. Wetzker: Linkage of
92. G protein-coupled receptors to the МАРК signaling pathway through PI 3-kinase. Science 275,394−397 (1997)
93. Crespo P., N. Xu, W. F. Symonds & J. S. Gutkind: Ras-dependent activation of
94. MAP kinase pathway mediated by G-protein beta gamma sub units. Nature 369, 418−420(1994)
95. Polakis P. & F. McCormick: Structural requirements for the interaction of p21raswith GAP, exchange factors, and its biological effector target. J Biol Chem 268, 9157−9160(1993)
96. Fujita-Yoshigaki J., M. Shirouzu, Y. Ito, S. Hattori, S. Furuyama, S. Nishimura & S.
97. Yokoyama: A constitutive effector region on the C-terminal side of switch I of the Ras protein. J Biol Chem 270,4661−4667 (1995)
98. Stokoe D., S. G. Mcdonald, K. Cadwallader, M. Symmons & J. F. Hancock:
99. Activation of Raf as a result of recruitment to the plasma membrane. Science 264, 1463−1467(1994)
100. Kyriakis J. M., H. App, X. Zhang, P. Banerjee, D. L. Brautigan, U. R. Rapp & J.
101. Avruch: Raf-1 activates MAP kinase-kinase. Nature 358,417−421 (1992)
102. Cowley S., H. Paterson, P. Kemp & C. J. Marshall: Activation of MAP kinase kinaseis necessary and sufficient for PC 12 differentiation and for transformation of NIH 3T3 cells. Cell 77, 841−852 (1994)
103. Ahn N. G., R. Seger, R. L. Bratlien, C. D. Diltz, N. K. Tonks & E. G. Krebs:
104. Multiple components in an epidermal growth factor-stimulated protein kinase cascade. In vitro activation of a myelin basic protein/microtubule associated protein 2 kinase. J Biol Chem 266,4220−4227 (1991)
105. Gomez N. & P. Cohen: Dissection of the protein kinase cascade by which nervegrowth factor activates MAP kinases. Nature 351, 69−72 (1991)
106. Kosako H., Y. Gotoh, S. Matsuda, M. Ishikawa & E. Nishida: Xenopus MAP kinaseactivator is a serine/threonine/tyrosine kinase activated by threonine phosphorylation. EMBO J11,2903−2908 (1992)
107. Nakielny S., P. Cohen, J. Wu & T. W. Sturgill: MAP kinase activator from insulinstimulated skeletal muscle is a protein threonine/tyrosine kinase. EMBO J11, 2123−2129 (1992)
108. Williams, N. G., and Roberts, Т. M. Signal transduction pathways involving the Rafproto-oncogene. (1994) Cancer Metastasis Rev. 13, 105−116.
109. Storm, S. M., Cleveland, J. L., and Rapp, U. R. Expression of raf family protooncogenes in normal mouse tissues (1990) Oncogene 5, 345−351
110. Stephens, R. M., Sithanandam, G., Copeland, T. D., Kaplan, D. R., Rapp, U. R., and
111. Morrison, D. K. 95-kilodalton B-Raf serine/threonine kinase: identification of the protein and its major autophosphorylation site (1992) Mo I. Cell. Biol. 12, 37 333 742.
112. Marais R., Y. Light, H. F. Paterson, C. S. Mason & C. J. Marshall: Differentialregulation of Raf-1, A-Raf, and B. Raf by oncogenic Ras and tyrosine kinases. J Biol Chem 272,4378−4383 (1997)
113. Katz M. E. & F. McCormick: Signal transduction from multiple Ras effectors. Curr
114. Opin Genet Dev 7,75−79 (1997)
115. Leevers S. J., H. F. Paterson & C. J. Marshall: Requirement for Ras in Raf activationis overcome by targeting raf to the plasma membrane. Nature 369,411−414 (1994)
116. Barnier J. V., Papin C., Eychene A. et al. The Mouse B-raf Gene Encodes Multiple
117. Protein Isoforms with Tissue-specific Expression. J. Biol. Chem. 1995- 270 (40): 23 381−23 389
118. Bogoyevitch M. A., Marshall C. J., Sugden P. H. Hypertrophic agonists stimulate theactivities of the protein kinases c-Raf and A-Raf in cultured ventricular myocytes. J. Biol. Chem. 1995- 270:26 303−26 310.
119. Nusse R., Varmus H. E. Many tumors induced by the mouse mammary tumor viruscontain a provirus integrated in the same region of the host genome. Cell 1982- 31: 99−109.
120. Behrens J., Jerchow B. A., Wurtele M. et al. Functional interaction of an axinhomolog, conducnin, with B-catenin, APC, and GSK3B. Science 1998- 280: 5969.
121. Groden J., Thliveris A., Samowitz W. et al. Identification and characterization of thefamilial adenomatous polyposis coli gene. Cell 1991- 66: 589−600.
122. Sparks А. В., Morin P. J., Vogelstein B. Mutational analysis of the APC/betacatenin/Tcf pathway in colorectal cancer. Cancer Res 1998- 58: 1130−4.
123. Korinek V., Barker N., Morin P. J. et al. Constitutive transcriptional activation by abeta-catenin-Tcf complex in APC -/- colon carcinoma. Science 1997- 275: 1784−7.
124. Su L. K., Burrell M., Hill D. E. et al. APC binds to the novel protein EB1. Cancer Res 1995−55:2972−7.
125. Smith K. J., Levy D. В., Maupin P. et al. Wild-type but not mutant APC associates with the microtubule cytoskeleton.
126. Cancer Res 1994- 54:3672−5.
127. Pulciani S., Santos E., Lauver A. et al. Oncogene in solid human tumors. Nature1982- 300: 539−542.
128. Feig L. A., Bast R. C., Knapp R. C. et al. Somatic activation of ras-K gene in ahuman ovarian carcinoma. Science 1984- 223: 698−701.
129. Rodenhuis S., van de Wetering M. L., Mooi W. J. et al. Mutational activation of the K-RAS oncogene: a possible pathogenetic factor in adenocarcinoma of the lung. New Eng. J. Med. 1987- 317: 929−935.
130. Takeda S., Ichii S., Nakamura Y. Detection of K-ras mutation in sputum by mutantallele-specific amplification (MASA). Hum. Mutat. 1993- 2: 112−7.
131. Ahrendt S. A., Decker P. A., Alawi E. A. et al. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary denocarcinoma of the lung. Cancer 2001- 92: 1525−30.
132. Keohavong P., Lan Q., Gao W. M. et al. K-ras mutations in lung carcinomas from nonsmoking women exposed to unvented coal smoke in China. Lung Cancer. 2003−41:21−7.
133. Nakano H., Yamamoto F., Neville C. et al. Isolation of transforming sequences of two human lung carcinomas: structural and functional analysis of the activated c-K-ras oncogenes. Proc. Nat. Acad. Sci. 1984- 81: 71−5.
134. Toyooka S., Tsukuda K., Ouchida M. et al. Detection of codon 61 point mutations of the K-ras gene in lung and colorectal cancers by enriched PCR. Oncol Rep. 2003- 10:1455−9.
135. Hilbe W., Dlaska M., Duba H. C. et al. Automated real-time PCR to determine K-ras codon 12 mutations in non-small cell lung cancer: comparison with immunohistochemistry and clinico-pathological features. Int J Oncol 2003- 23: 1121−6.
136. Grossi F., Loprevite M., Chiaramondia M. et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers. Eur J Cancer 2003−39:1242−50.
137. Ramirez J. L., Sarries C., de Castro P. L. et al. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 2003- 193: 207−16.
138. Kovalchuk О., Chyczewska E., Niklinska W. et al. K-ras codon 12 mutations detected with enriched PCR method in operable non-small cell lung cancer. Folia Histochem Cytobiol. 2001- 39 Suppl 2: 68−9.
139. Miyakis S., Sourvinos G., Spandidos D. A. Differential expression and mutation ofthe ras family genes in human breast cancer. Biochem Biophys Res Commun. 1998−251:609−12.
140. Burmer G. C., Loeb L. A. Mutations in the KRAS2 oncogene during progressivestages of human colon carcinoma. Proc. Nat. Acad. Sci. 1989- 86: 2403−7.
141. Sidransky D., Tokino Т., Hamilton S. R. et al. Identification of RAS oncogene mutations in the stool of patients with curable colorectal tumors. Science 1992- 256: 102−5.
142. Otori K., Oda Y., Sugiyama K. et al. High frequency of K-ras mutations in humancolorectal hyperplastic polyps. Gut 1997- 40: 660−3.
143. Vogelstein В., Fearon E. R., Hamilton S. et al. Genetic alterations duringcolorectal-tumor development. N Engl J Med 1988- 319: 525−532.
144. Fearon E. R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell1990−61:759−767.
145. Mendelsohn J., Howley P. M., Israel M. A. et al. The molecular basis of cancer. 2ndedition. W. B. Saunders Company. 2001, p. 300.
146. Rajagopalan H., Bardelli A., Lengauer C. et al. RAF/RAS oncogenes andmismatch-repair status. Nature 2002- 418: 934 only.
147. Chan T. L., Zhao W., Leung S. Y. et al. Cancer Genome Project. BRAF and KRASmutations in colorectal hyperplastic polyps and serrated adenomas. Cancer Res. 2003−63:4878−81.
148. Yuen S. Т., Davies H., Chan T. L. et al. Similarity of the phenotypic patternsassociated with BRAF and KRAS mutations in colorectal neoplasia. Cancer Res. 2002−62:6451−5.
149. Fransen K., Klintenas M., Osterstrom A, et al. Mutation analysis of the BRAF,
150. ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis. 2003 Epub ahead of print.
151. Lindforss U., Papadogiannakis N., Zetterquist H. et al. Distribution of geneticvariants in preneoplastic areas of colorectal tumours. Eur J Surg Oncol. 2003- 29: 491−6.
152. Almoguera C., Shibata D., Forrester K. et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988- 53: 549−54.
153. Hruban R. H., Goggins M., Parsons, et al. Genetic progression in the pancreatic ducts (Commentary). Clin. Cancer Res 2000- 6: 2969−72.
154. Hruban R. H., Wilentz R. E., Kern S. E. Genetic progression in the pancreatic ducts. Am. J. Pathol. 2000- 156:1821−5.
155. Laghi L., Orbetegli O., Bianchi P. et al. Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene 2002- 21: 4301−6.
156. Smit V. Т. H. В. M., Boot A. J. M., Smits A. M. M. et al. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res. 1988- 16: 7773−82.
157. Motojima K., Urano Т., Nagata Y. et al. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann. Surg. 1993- 217: 138−43.
158. Sugio К., Molberg К., Albores-Saavedra J. et al. K-Ras mutations and allelic loss at 5q and 18q in the development of human pancreatic cancers. Int J Pancreatol 1997−21:205−17.
159. Matsubayashi H., Watanabe H., Nishikura K. et al. Determination of pancreatic ductal carcinoma histogenesis by analysis of mucous quality and K-Ras mutation. Cancer 1998- 82:651−60.
160. Luttges J, Schlehe В, Menke M, et al: The K-Ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic and metaplastic epithelium. Cancer 1999- 85: 1703−10.
161. Schaeffer В. K., Glasner S., Kuhlmann E. et al. Mutated c-K-Ras in small pancreatic adenocarcinomas. Pancreas 1994- 9: 161−5.
162. Liu E., Hjelle В., Morgan R. et al. Mutations of the Kirsten-ras proto-oncogene in human preleukaemia. Nature 1987- 330: 186−8.
163. Bollag G., Adler F., el Masry N. et al. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J. Biol. Chem. 1996- 271: 32 491−4.
164. Bezieau S., Devilder M.-C., Avet-Loiseau H. et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum. Mutat. 2001- 18: 212−24.
165. Sithanandam G., Kolch W., Duh F. M. et al. Complete coding sequence of a human B-raf cDNA and detection of B-raf protein kinase with isozyme specific antibodies. Oncogene 1990- 5: 1775−80.
166. Ikawa S., Fukui M., Ueyama Y. et al. B-raf, a new member of the raf family, is activated by DNA rearrangement. Mol Cell Biol 1988- 8: 2651−4.
167. Eychene A., Barnier J. V., Apiou F. et al. Chromosomal assignment of two human B-raf (Rmil) proto-oncogene loci: B-raf-1 encoding the p94(Braf/Rmil) and B-raf-2, a processed pseudogene. Oncogene 1992- 7: 1657−60.
168. Sithanandam G., Druck Т., Cannizzaro L. A. et al. B-raf and a B-raf pseudogene are located on 7q in man. Oncogene 1992- 7: 795−799.
169. Davies H., Bignell G. R., Cox C. et al. Mutations of the BRAF gene in human cancer. Nature 2002- 417: 949−954.
170. Hingorani S. R., Jacobetz M. A., Robertson G. P. et al. Suppression of BRAF (V599E) in human melanoma abrogates transformation. Cancer Res. 2003- 63: 5198−202.
171. Brose M. S., Volpe P., Feldman M. et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 2002- 62: 6997−7000.
172. Naoki K., Chen Т. H., Richards W. G. et al. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 2002- 62: 7001−3.
173. Edmunds S. С., Cree I. A., Di Nicolantonio F. et al. Absence of BRAF gene mutations in uveal melanomas in contrast to cutaneous melanomas. Brit. J. Cancer 2003- 88: 1403−5.
174. Cohen Y., Goldenberg-Cohen N., Parrella P. et al. Lack of BRAF mutation in primary uveal melanoma. Invest Ophthalmol Vis Sci. 2003- 44: 2876−8.
175. Cruz F. 3rd, Rubin B. P., Wilson D. et al. Absence of BRAF and NRAS mutations in uveal melanoma. Cancer Res. 2003- 63: 5761−6.
176. Weber A., Hengge U. R., Urbanik D. et al. Absence of Mutations of the BRAF Gene and Constitutive Activation of Extracellular-Regulated Kinase in Malignant Melanomas of the Uvea. Lab Invest. 2003- 83: 1771−6.
177. Rimoldi D., Salvi S., Lienard D. et al. Lack of BRAF mutations in uveal melanoma. Cancer Res. 2003- 63: 5712−5.
178. Pollock P. M., Harper U. L., Hansen K. S. et al. High frequency of BRAF mutations in nevi. Nature Genet. 2003- 33: 19−20.
179. Uribe P., Wistuba I. I., Gonzalez S. BRAF mutation: a frequent event in benign, atypical, and malignant melanocytic lesions of the skin. Am J Dermatopathol. 2003- 25: 365−70.
180. Yazdi A. S., Palmedo G., Flaig M. J. et al. Different frequencies of a BRAF point mutation in melanocytic skin lesions. Pigment Cell Res. 2003- 16: 580.
181. Kumar R., Angelini S., Hemminki K. Activating BRAF and N-Ras mutations in sporadic primary melanomas: an inverse association with allelic loss on chromosome 9. Oncogene. 2003- 22: 9217−24.
182. Dong J., Phelps R. G., Qiao R. et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003- 63: 3883−5.
183. Gorden A., Osman I., Gai W. et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res. 2003- 63: 3955−7.
184. Omholt K" Platz A., Kanter L. et al. NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression. Clin Cancer Res. 2003- 9: 6483−8.
185. Lang J., Boxer M., MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum Mutat. 2003- 21: 327−30.
186. Meyer P., Klaes R., Schmitt C. et al. Exclusion of BRAF V599E as a melanoma susceptibility mutation. Int J Cancer. 2003- 106: 78−80.
187. Laud K., Kannengiesser C., Avril M. F. et al. BRAF as a melanoma susceptibility candidate gene? Cancer Res. 2003- 63: 3061−5.
188. Meyer P., Sergi C., Garbe C. Polymorphisms of the BRAF gene predispose males to malignant melanoma. J Carcinog. 2003 Nov 14 Epub ahead of print.
189. Cohen Y., Xing M., Mambo E. et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 2003- 95: 625−7.
190. Kimura E. Т., Nikiforova M. N., Zhu Z. et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003- 63: 1454−7.
191. Soares P., Trovisco V., Rocha A. S. et al. BRAF mutations and RET/PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003- 22: 4578−80.
192. Xu X., Quiros R. M., Gattuso P. et al. High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 2003- 63: 4561−7.
193. Namba H., Nakashima M., Hayashi T. et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003- 88: 4393−7.
194. Fukushima Т., Suzuki S., Mashiko M. et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003- 22: 6455−7.
195. Lee S. H., Lee J. W., Soung Y. H. et al. BRAF and KRAS mutations in stomach cancer. Oncogene. 2003- 22: 6942−5.
196. Oliveira C., Pinto M., Duval A. et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene. 2003- 22: 9192−6.
197. Kim I. J., Park J. H., Kang H. C. et al. Mutational analysis of BRAF and K-ras in gastric cancers: absence of BRAF mutations in gastric cancers. Hum Genet. 2003- 114: 118−20.
198. Singer G., Oldt R. 3rd, Cohen Y. et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. Natl Cancer Inst. 2003- 95:484−6.
199. Gemignani M. L., Schlaerth A. C., Bogomolniy F. et al. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma. Gynecol Oncol. 2003- 90: 378−81.
200. Calhoun E. S., Jones J. В., Ashfaq R. et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol. 2003- 163: 1255−60.
201. Tannapfel A., Sommerer F., Benicke M. et al. Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. Gut. 2003- 52: 706−12.
202. Nagase H., Nakamura Y. Mutations of APC (adenomatous polyposis coli) gene. Hum Mutat 1993- 2:425−34.
203. Cottrell S., Bicknell D., Kaklamanis L. et al. Molecular analysis of APC mutations in familial adenomatous polyposis and sporadic colon carcinomas. Lancet 1992- 340: 626−30.
204. Yuan P., Sun M. H., Zhang J. S. et al. APC and K-ras gene mutation in aberrant crypt foci of human colon. World J Gastroenterol. 2001- 7: 352−6.
205. Powell S. M., Zilz N., Beazer-Barclay Y. et al. APC mutations occur early during colorectal tumorigenesis. Nature. 1992- 359: 235−7.
206. Miyoshi Y. Nagase H, Ando H. et al. Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1992- 1:229−33.
207. Beroud C., Soussi T. APC gene: database of germline and somatic mutations in human tumors and cell lines. Nucleic Acids Res 1996- 24: 121−4.
208. Nakatsuru S., Yanagisawa A., Ichii S. et al. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum Mol Genet. 1992- 1: 559−63.
209. Nakatsuru S., Yanagisawa A., Furukawa Y. et al. Somatic mutations of the APC gene in precancerous lesion of the stomach. Hum Mol Genet. 1993- 2: 1463−5.
210. Tamura G., Maesawa C., Suzuki Y. et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res. 1994- 54:1149−51.
211. Lee J. H., Abraham S. C., Kim H. S. et al. Inverse relationship between APC gene mutation in gastric adenomas and development of adenocarcinoma. Am J Pathol. 2002- 161:611−8.
212. Furuuchi K., Tada M., Yamada H. et al. Somatic mutations of the APC gene in primary breast cancers. Am J Pathol. 2000- 156: 1997−2005.
213. Yashima K., Nakamori S., Murakami Y. et al. Mutations of the adenomatous polyposis coli gene in the mutation cluster region: comparison of human pancreatic and colorectal cancers. Int J Cancer. 1994- 59: 43−7.
214. Horii A., Nakatsuru S., Miyoshi Y. et al. Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res. 1992- 52: 6696−8.
215. Leon S. A., Shapiro В., Sklaroff D. M. et al. Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 1977- 37: 646 650.
216. Maebo A. Plasma DNA level as a tumor marker in primary lung cancer. Jap J Thoracic Dis 1990- 28: 1085- 1091.
217. Fournie G. J., Courtin J. P., Laval F. Plasma DNA as a marker of cancerous cell death. Investigation in patients suffering from lung cancer and in nude mice bearing human tumour. Cancer Let 1995- 2: 221 227.
218. Stroun M., Anker P., Lyautey J. Isolation and characterization of DNA from the plasma of cancer patients. Eur. J. Cancer Clin. Oncol. 1987- 23: 707−12.
219. Stroun M., Lyautey J., Lederrey A. et al. About the possible origin and mechanism of circulating DNA. Apoptosis and active DNA release. Clin. Chem. Acta 2001- 313: 139−142.
220. Bevilacqua R. A., Nunes D. N., Stroun M. et al. The use of genetic instability as a clinical tool for cancer diagnosis. Semin Cancer Biol. 1998- 8:447−53.
221. Steinman C. R. Free DNA in serum and plasma from normal adults. J Clin Invest1975−56:512−515.
222. Kopreski M. S., Benko F. A., Rwee C. et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer 1997- 76: 1293−9.
223. Mulcahy H., Anker P., Lyautey J. et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998- 4: 271−5.
224. Yamada Т., Nakamori S., Ohzato H. et al. Circulating DNA K-ras mutation in pancreatic adenocarcinoma. Clin Cancer Res 1998- 4: 1527−32.
225. Hibi K., Robinson C. R., Booker S. et al. Molecular detection of genetic alterationsin the serum of colorectal cancer patients. Cancer Res 1998- 58: 1405−7.
226. Lam N. Y., Rainer Т. H., Chiu R. W. et al. EDTA is a better anticoagulant than heparin or citrate for delayed blood processing for plasma DNA analysis. Clin Chem 2004- 50:256−7.
227. Alvibac M., Filotico R., Gianella C. et al. The effect of fixation type on DNA extracted from paraffin-embedded tissue for PCR studies in dermatopathology. Dermatology 1997- 195: 105−107.
228. Barnard R., Futo V., Pecheniuk. M et al. PCR bias toward the wild-type k-ras and p53 sequences: implications for PCR detection of mutations and cancer diagnosis. Biotechniques 1998- 25: 684−91.
229. Ward R., Hawkins N., O’Grady R. et al. Restriction endonuclease-mediated selective polymerase chain reaction. A novel assay for detection of K-ras mutations in clinical samples. Am J Pathol. 1998- 153: 373−9.
230. Burns W. C., Liu Y. S., Dow C. et al. Direct PCR from paraffin-embedded tissue. Biotechniques 1997- 22: 638−40.
231. Roberts N. J., Impey T. L., Applegate T. L. et al. Rapid, sensitivedetection of mutant alleles in codon 12 of K-ras by REMS-PCR. Biotechniques 1999- 27: 41 822.
232. Mulcahy H. E., Lyautey J., Lederrey C. et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res 1998- 4: 271−5.
233. Kahn S. M., Jiang W. Culbertson T. A. et al. Rapid and sensitive nonradioactive detection of mutant K-ras genes via «enriched» PCR amplification. Oncogene 1991- 6: 1079−83.
234. McGrath J. P., Capon D. J., Smith D. H. et al. Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature 1983- 304 (5926): 501−6.215. http://p53.curie.fr/p53 site version 2.0/APCdatabase.html
235. Servomaa K., Kiuru A., Kosma V.-M. et al. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 2000- 53: 24−30.
236. Garicochea В., Giorgi R., Odone V. F. et al. Mutational analysis of N-Ras and GAP-related domain of the neurofibromatosis type 1 gene in chronic myelogenous leukemia. Leukemia Res 1998- 22: 1003−7.
237. Corradini P., Ladetto M., Voena C. et al. Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasias. Blood 1993- 81: 2708−13.
238. Shinozaki M., O’Day S., Kuo C. et al. Detection and clinical utility of Braf mutation in serum of melanoma patients. Circulating Nucleic Acid in Plasma and Serum 3rd Congress. John Wayne Cancer Institute, Santa Monica, CA, USA. November 9−12,2003.
239. Белохвостов А. С., Румянцев А. Г. Онкомаркеры. Москва: МАКС Пресс, 2003.
240. Alguacil J., Porta M., Malats N. et al. Occupational exposure to organic solvents and K-ras mutations in exocrine pancreatic cancer. Carcinogenesis 2002- 23: 1016.
241. Tada M., Omata M., Kawai S. et al. Detection of ras gene mutations in pancreatic juice and blood of patients with pancreatic adenocarcinoma. Cancer Res 1993- 53: 2472−4.
242. Lecomte Т., Berger A., Zinzindohoue F. et al. Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. Int J Cancer 2002- 100: 542−8.
243. Saetta A. A., Papanastasiou P., Michalopoulos N. V. et al. Mutational analysis of Braf in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. Virchows Arch 2004- Jun 19.
244. Kim J. С., Foxworth A., Waldman T. et al. B-raf is dispensable for K-ras-mediated oncogenesis in human cancer cells. Cancer Res 2004- 64: 1932−7.
245. Rykova Е. Y., Laktionov P. P., Skvortsova Т. Е. et al. Extracellular DNA in breast cancer: Cell-surface-bound, tumor-derived extracellular DNA in blood of patients with breast cancer and nonmalignant tumors. Ann N Y Acad Sci 2004- 1022: 21 720.
246. Schlechte H. H., Stelzer C., Weickmann S. et al. TP53 gene in blood plasma DNA of tumor patients. Ann N Y Acad Sci 2004- 1022: 61−9.
247. F. Lalloo. Genetics for Oncologists. Remedica Publishing Limited 2002.
248. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. Mol Biol 1967- 26: 365−9.
249. Malumbres M., Pellicer A. RAS PATHWAYS TO CELL CYCLE CONTROL AND CELL TRANSFORMATION. Front in Biosci 1998- 3: 887−912.
250. Sulston J. E., Waterston R. Toward a complete human genome sequence. Genome Res. 1998- 8: 1097−108
251. International Human Genome Sequencing Consortium. The DNA sequence of Homo sapiens. 2003.